0
Veterinarians and farmers across the globe have reached the landmark of protecting one billion sows and pigs against the potentially devastating effects of Porcine Reproductive and Respiratory Syndrome (PRRS) using Ingelvac PRRS MLV ®. The vaccine, which was launched in 1994 in the USA, is currently marketed in 19 countries in Asia, Europe, and North America. It contributes to securing the pigs’ health as well as providing healthy pork for consumers around the world.
PRRS is considered as being one of the severest swine diseases– both from a herd health and an economic perspective. Every year an estimated 1.5 billion pigs are affected by this disease globally.1 With vaccination the economic impact of PRRS, which is higher than 10€/pig in 90% of the cases,2 can be reduced. Prevention of PRRS and other diseases through vaccination not only leads to more efficient livestock farming; it also reduces the need for antibiotics leading to an improved quality of food from animal origin.
Ingelvac PRRS MLV® is a modified live vaccine against PRRS type II that has allowed veterinarians and farmers to increase the productivity of their farms by reducing or eliminating the negative outcomes of a PRRS infection: abortions, piglet mortality, respiratory problems and reduced growth of pigs.
Ingelvac PRRS MLV® is a well established brand globally. It is customers’ number one choice for vaccinating pigs against PRRS in particular because of its safety and efficacy together with the support services provided by Boehringer Ingelheim Animal Health.3
1. Based on local and international market research data (data on file).
2. Dennis DiPietre. “Understanding the hidden impact of PRRS”. 9th Asian PRRSpective, 2015.
3. Based on local and international market research data (data on file).
September 26, 2016 - Boehringer
